Timothy Patrick Flynn, a director at UnitedHealth Group Inc. (NYSE:UNH), recently purchased 1,000 shares of the company’s common stock. The transaction, dated January 17, 2025, was made at a price of $511.575 per share, totaling approximately $511,575. According to InvestingPro analysis, the stock appears undervalued compared to its Fair Value, with analysts maintaining a strong buy consensus and a potential upside of 22%. Following this acquisition, Flynn holds a total of 4,500 shares indirectly through a trust. UnitedHealth Group, based in Eden Prairie, Minnesota, is a prominent player in the healthcare services industry, with a market capitalization of $477 billion and annual revenue exceeding $400 billion. InvestingPro data reveals that management has been actively buying back shares, and the company maintains an impressive 32-year streak of consistent dividend payments. For deeper insights into UNH’s insider trading patterns and comprehensive analysis, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.
In other recent news, UnitedHealth Group has been a focal point in several recent developments. The company reported its fourth-quarter earnings with an adjusted earnings per share (EPS) of $6.81, slightly exceeding consensus estimates by 1%, and revenue matching expectations at $100.8 billion. UnitedHealth Group and Amedisys (NASDAQ:AMED) have also extended their merger deadline amid scrutiny from the U.S. Department of Justice, a move that could expand UnitedHealth’s presence in the home health sector.
KeyBanc Capital Markets and Piper Sandler have both maintained their positive stances on UnitedHealth, reiterating their Overweight ratings. Bernstein analysts also maintained their Outperform rating on the company’s shares. These ratings were largely based on UnitedHealth’s solid performance and potential for growth, particularly in the Medicare Advantage sector.
Additionally, the Federal Trade Commission (FTC) released a report revealing significant price markups on specialty generic drugs by three major pharmacy benefit managers (PBMs), including OptumRx, which is owned by UnitedHealth. Furthermore, a government proposal could lead to increased payments for Medicare Advantage plans in 2026, potentially benefiting companies like UnitedHealth. These are the recent developments for UnitedHealth Group.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.